Risk Factors Associated With Calcification of the Aortic Valve
The purpose of this study is
- to determine the degree of endothelial dysfunction and inflammation in calcific aortic valve disease associated with coronary artery disease(CAD).
- to determine whether there is relationship between calcium metabolism and calcific aortic valve disease associated with CAD.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease|
|Study Start Date:||January 2005|
|Estimated Study Completion Date:||December 2008|
Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
Cardiovascular disease, mainly coronary artery disease, causes more than one half of deaths in the developed countries. Only recently, calcific aortic valve disease, was proved to belong to the family of atherosclerosis. It is associated with higher cardiovascular morbidity and mortality, the cause of which is not entirely clear. The link to significant coronary artery disease, probably, is of highest importance.
We compare groups of patients with coronary artery disease and calcific stenotic, sclerotic or intact aortic valve. The aim is to assess and compare their risk profile to verify our hypothesis that, within significant coronary artery disease, calcific aortic valve identifies a subgroup of patients with higher cardiovascular risk, assessed by endothelial dysfunction and the two year follow-up of cardiovascular events on optimally set treatment.
Further, we study the possible association of valvular calcification and calcium metabolism in patients with normal kidney function.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375336
|Charles University of Prague, School of Medicine, Plzen|
|Plzen, Czech Republic, 304060|
|Principal Investigator:||Katerina Linhartova, MD, PhD||Charles University of Prague, School of Medicine Pilsen, Czech Republic|
|Study Chair:||Roman Cerbak, Prof,MD,PhD||Center for Cardiovascular and Transplantation Surgery, Brno, Czech Republic|